312 related articles for article (PubMed ID: 22182854)
21. Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
MacDonald RJ; Bunaciu RP; Ip V; Dai D; Tran D; Varner JD; Yen A
Leuk Lymphoma; 2018 Dec; 59(12):2941-2951. PubMed ID: 29569971
[TBL] [Abstract][Full Text] [Related]
22. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
23. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
[TBL] [Abstract][Full Text] [Related]
24. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
26. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
27. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
29. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
30. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Nayak S; Shen M; Bunaciu RP; Bloom SE; Varner JD; Yen A
Leuk Lymphoma; 2010 Sep; 51(9):1734-47. PubMed ID: 20615082
[TBL] [Abstract][Full Text] [Related]
32. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
33. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
34. The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
Shi R; Lin J; Guo Y; Gong YP
Pharmazie; 2014 May; 69(5):346-52. PubMed ID: 24855825
[TBL] [Abstract][Full Text] [Related]
35. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
36. 6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.
Bunaciu RP; Jensen HA; MacDonald RJ; LaTocha DH; Varner JD; Yen A
PLoS One; 2015; 10(8):e0135668. PubMed ID: 26287494
[TBL] [Abstract][Full Text] [Related]
37. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
38. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
Gallagher AP; Burnett AK; Bowen DT; Darley RL
Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.
Mise J; Dembitz V; Banfic H; Visnjic D
Pathol Oncol Res; 2011 Sep; 17(3):645-56. PubMed ID: 21336564
[TBL] [Abstract][Full Text] [Related]
40. Thrombin-induced NF-κB activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.
Lin CH; Yu MC; Chiang CC; Bien MY; Chien MH; Chen BC
Cell Signal; 2013 May; 25(5):1166-75. PubMed ID: 23357535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
